Notice of results

LONDON, UK, 3 August 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, will announce its interim financial results for the six months ended 30 June 2017 on Thursday 17 August 2017.

A presentation and webcast for analysts will be held at 9.30am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

To join via conference call please dial:

Standard International Access

+44 (0) 20 3003 2666

UK Toll Free

0808 109 0700

USA Toll Free

+1 866 966 5335

New York, New York

+1 212 999 6659

Password: Hikma

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com.  

Details of a playback of the conference call will be available on the Company's website following the meeting.

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Director of Investor Relations

 +44 (0)20 7399 2760/ +44 7776 477050

Lucinda Baker, Deputy Director of Investor Relations

+44 (0)20 7399 2765/ +44 7818 060211

FTI Consulting

Ben Atwell / Brett Pollard +44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Injectables", "Generics" and "Branded", based primarily in the Middle East and North Africa ("MENA") region, the United States and Europe. In 2016, Hikma achieved revenue of $1,950 million and profit attributable to shareholders of $155 million.